Serine protease inhibitor kazal type 1 (spink1) promotes proliferation, migration, invasion and radiation resistance in rectal cancer patients receiving concurrent chemoradiotherapy: a potential target for precision medicine

HIGHLIGHTS

  • who: Yi-Ting Chen from the Department of Radiation Oncology, Faculty of Medicine, College of Medicine, Taiwan have published the Article: Serine protease inhibitor Kazal type 1 (SPINK1) promotes proliferation, migration, invasion and radiation resistance in rectal cancer patients receiving concurrent chemoradiotherapy: a potential target for precision medicine, in the Journal: (JOURNAL)
  • what: The aim in this study was to demonstrate the clinicopathological role and progression of in rectal cancer (RC) patients undergoing concurrent chemoradiotherapy (CCRT). The chi-square analysis in the study showed that high pre-CCRT SPINK1 expression was significantly associated with PNI . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?